Article info
PDFFeature article
Should rare diseases get special treatment?
- Correspondence to Dr. Monica Magalhaes, Center for Population-Level Bioethics, Rutgers University, New Brunswick, NJ 08901, USA; monica.magalhaes{at}rutgers.edu
Citation
Should rare diseases get special treatment?
Publication history
- Received June 26, 2021
- Accepted November 1, 2021
- First published November 23, 2021.
Online issue publication
January 21, 2022
Article Versions
- Previous version (23 November 2021).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis
- A fair share for the orphans: ethical guidelines for a fair distribution of resources within the bounds of the 10-year-old European Orphan Drug Regulation
- Societal views on orphan drugs: cross sectional survey of Norwegians aged 40 to 67
- Rare neurological diseases: a practical approach to management
- Rare diseases in healthcare priority setting: should rarity matter?
- Orphan drugs and the NHS: should we value rarity?
- Rare childhood diseases: how should we respond?
- Does NICE apply the rule of rescue in its approach to highly specialised technologies?
- Criteria to define rare diseases and orphan drugs: a systematic review protocol
- Double bad luck: Should rare diseases get special treatment?